Repetitive Behaviors Also Significantly Decrease
NEW YORK, NY. (December 8, 2011) — A new study led by Dr. Eric Hollander, Chairman of the Advisory Council of The International Center for Autism Research and Education (ICare4Autism), demonstrates for the first time that the antidepressant fluoxetine produces an improvement in overall functioning and a decrease in repetitive behaviors in a significant number of adults with autism spectrum disorders.
The study, funded by the Orphan Products Division of the Food and Drug Administration (FDA), will be published this month in The American Journal of Psychiatry, the official journal of the American Psychiatric Association. Its findings have important clinical implications.
To read the full article in The American Journal of Psychiatry, click here.
Notes Dr. Hollander, Director of the Autism Spectrum Program of the Albert Einstein College of Medicine/Montefiore Medical Center in New York City, “While research on medications for the core features of autism spectrum disorders is still in the early stages, successful treatments could greatly improve the daily lives of patients and their families.”
ICare4Autism founder and CEO Dr. Joshua Weinstein hailed the new study as “groundbreaking work that will lead to novel therapeutic interventions with the potential to help the vast and rapidly growing population of adults with autism all over the world.”
Contact: Kim Robinson email@example.com